- Email: [email protected]
Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
Pa tent reports the sequences of the RNA ligands identified. The modified RNA ligands to thrombin exhibit increased in viva stability. Recombinant Human Thymopoietin Proteins and Its Uses Culler ef al. Immunobiology Research Institute, Inc. US 5472856; December 5, 1995 Nucleotide and amino acid sequences for human thymopoietin alpha, beta, and gamma and methods for their recombinant expression. The diagnostic and therapeutic uses of these proteins. Methods for Identifying Nucleic Acid Ligands of Human Neutrophil Elastase Gold et al. NeXstar Pharmaceuticals, Inc. US 5472841; December 5, 1995 Methods for the identification and preparation of nucleic acid ligands to human neutrophil elastase. Included in the invention are specific RNA and DAN ligands to elastase identified by the SELEX method. Transdominant Negative Proto-Oncogene Venna et al. Salk Institute for Biological Studies US 5470736; November 28, 1995 Polynucleotide and polypeptide sequences for a transrepressing protein of the Fos protooncogene family where the polypeptide is characterized by having a leucine zipper domain and forming a heterodimer with a Jun-related protein. This heterodimer is capable of binding to an AP-1 site and suppressing transcriptional transactivation of a promoter containing the AP-1 site. HIV Antibody Assays Comprising P24-GP41 Chimeric Antigens Drevin et al. Pharmacia Genetic Engineering, Inc. US 5470720; November 28, 1995 A DNA segment encoding a recombinant HIV p24 protein or HIV p24-gp41 fusion protein and a recombinant DNA (rDNA) molecule capable of expressing either protein. Cells transformed with the rDNA, methods for producing the fusion protein, and diagnostic methods and systems using the fusion protein are also described.
Pharmaceuticals Methods for Producing Thrombin Foster et al. ZymoGenetics, Inc. US 5476777; December 19, 1995 Methods for producing tbrombin. The protein is produced from host cells transformed or transfected with DNA constructs containing information necessary to direct the expression of thrombin precursors. The DNA constructs generally include the following operably linked elements: a transcriptional promoter, DNA sequence encoding a gla-domainless prothrombin, and a transcriptional terminator. Thrombin precursors produced from transformed or transfected host cells are activated either in vivo or in vitro. Noncolorimetric Histoculture Method for Predicting Drug Response of Tumors Connors et al. Anticancer, Inc. US 5474909; December 12, 1995 A method of evaluating the effectiveness of drugs in inhibiting the growth of tumor cells. A sample of a tumor is histocultured, a drug
630
Enzyme Microb. Technol.,
1996, vol. 19, December
to be evaluated is added to the sample, and the sample is incubated. A suitable tetrazolium salt is added and a frozen section of the sample is prepared. The section is stained with a fluorescent dye and exposed to polarized light. The reflected light is then measured. The section is then exposed to fluorescent light and the light emitted by the dye is measured. These measurements are compared to a control and/or measurements from tests using other drugs and the relative effectiveness of the drug is evaluated preferably by pixel analysis.
Methods and Compositions for Inhibition of Hepatic Clearance of Tissue-Type Plasminogen Activator Bu et al. Washington Universiv US 5474766; December 12, 1995 Methods and compositions for inhibiting the hepatic clearance of tissue-type plasminogen activator (t-PA) in vivo by administering a t-PA-hepatic clearance-inhibiting amount of 39 kDa protein or a t-PA-hepatic clearance-inhibiting fragment, or genetically or chemically modified forms of the 39 kDa protein or fragments. Methods and compositions for treatment of thrombolytic diseases by administering t-PA and a tPA-hepatic clearance-inhibiting effective amount of 39 kDa protein, a t-PA-hepatic clearance inhibiting fragment, and genetically or chemically modified forms of the 39 kDa protein or its fragments are described.
Pro-Urokinase Mutants Gurewich et al. New England Deaconess Hospital US 5472692; December 5, 1995 Thrombolytically active pro-urokinase (pro-UK) mutants comprising the amino acid sequence of native pro-UK, but including a mutation which causes the pro-UK mutants to induce less fibrinogenolysis and nonspecific plasminogen activation than native proUK and to have at least a tenfold lower intrinsic activity than native pro-UK, and substantially the same fibrin promotion and thrombolytic activity after plasmin activation compared to native pro-UK when administered to a patient.
Method of Treating Human EGF Receptor-Expressing Gliomas Using Radiolabeled EGF Receptor-Specific MAB 425 Herlyn et al. The Wistar Institute US 5470571; November 28, 1995 Monoclonal antibody 425 having properties particularly beneficial for anti-tumor therapy. MAb 425 antibody binds to EGF receptors and inhibits their bioactivities. The amount of binding of the antibody to cancer cells can be increased by treatment of the cells with lymphokine preparations. Radiolabeled MAb 425 is used for treatment of EGF receptor-expressing gliomas.
Recombinant Colony-Stimulating Factor-l Coyne et al. Cetus Oncology Corporation US 5470569; November 28, 1995 A colony-stimulating factor. CSF-1, is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods which include cloning and expression of the murine and human DNA sequences encoding this protein.
Pharmaceuticals Methods for Producing Thrombin Foster et al. ZymoGenetics, Inc. US 5476777; December 19, 1995 Methods for producing tbrombin. The protein is produced from host cells transformed or transfected with DNA constructs containing information necessary to direct the expression of thrombin precursors. The DNA constructs generally include the following operably linked elements: a transcriptional promoter, DNA sequence encoding a gla-domainless prothrombin, and a transcriptional terminator. Thrombin precursors produced from transformed or transfected host cells are activated either in vivo or in vitro. Noncolorimetric Histoculture Method for Predicting Drug Response of Tumors Connors et al. Anticancer, Inc. US 5474909; December 12, 1995 A method of evaluating the effectiveness of drugs in inhibiting the growth of tumor cells. A sample of a tumor is histocultured, a drug
630
Enzyme Microb. Technol.,
1996, vol. 19, December
to be evaluated is added to the sample, and the sample is incubated. A suitable tetrazolium salt is added and a frozen section of the sample is prepared. The section is stained with a fluorescent dye and exposed to polarized light. The reflected light is then measured. The section is then exposed to fluorescent light and the light emitted by the dye is measured. These measurements are compared to a control and/or measurements from tests using other drugs and the relative effectiveness of the drug is evaluated preferably by pixel analysis.
Methods and Compositions for Inhibition of Hepatic Clearance of Tissue-Type Plasminogen Activator Bu et al. Washington Universiv US 5474766; December 12, 1995 Methods and compositions for inhibiting the hepatic clearance of tissue-type plasminogen activator (t-PA) in vivo by administering a t-PA-hepatic clearance-inhibiting amount of 39 kDa protein or a t-PA-hepatic clearance-inhibiting fragment, or genetically or chemically modified forms of the 39 kDa protein or fragments. Methods and compositions for treatment of thrombolytic diseases by administering t-PA and a tPA-hepatic clearance-inhibiting effective amount of 39 kDa protein, a t-PA-hepatic clearance inhibiting fragment, and genetically or chemically modified forms of the 39 kDa protein or its fragments are described.
Pro-Urokinase Mutants Gurewich et al. New England Deaconess Hospital US 5472692; December 5, 1995 Thrombolytically active pro-urokinase (pro-UK) mutants comprising the amino acid sequence of native pro-UK, but including a mutation which causes the pro-UK mutants to induce less fibrinogenolysis and nonspecific plasminogen activation than native proUK and to have at least a tenfold lower intrinsic activity than native pro-UK, and substantially the same fibrin promotion and thrombolytic activity after plasmin activation compared to native pro-UK when administered to a patient.
Method of Treating Human EGF Receptor-Expressing Gliomas Using Radiolabeled EGF Receptor-Specific MAB 425 Herlyn et al. The Wistar Institute US 5470571; November 28, 1995 Monoclonal antibody 425 having properties particularly beneficial for anti-tumor therapy. MAb 425 antibody binds to EGF receptors and inhibits their bioactivities. The amount of binding of the antibody to cancer cells can be increased by treatment of the cells with lymphokine preparations. Radiolabeled MAb 425 is used for treatment of EGF receptor-expressing gliomas.
Recombinant Colony-Stimulating Factor-l Coyne et al. Cetus Oncology Corporation US 5470569; November 28, 1995 A colony-stimulating factor. CSF-1, is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods which include cloning and expression of the murine and human DNA sequences encoding this protein.